Exploring Natural Compounds Targeting the Bacterial SHV Protein to Combat Antibiotic Resistance: A Biocomputational Study

Farah Anjum, Hamsa Jameel Banjer, Nahed Hawsawi, Fouzeyyah Ali Alsaeedi, Ahad Amer Alsaiari, Afaf Alharthi, Abdulraheem Ali Almalki, Maram Jameel Hulbah, Norah Alharthi, Alaa Shafie, Maha Bakhuraysah

Abstract


Background: Antibiotic-resistant (AR) bacteria are rapidly spreading worldwide, posing a serious threat to antibiotic efficacy. Bacterial infections have emerged as a persistent threat following decades of antibiotic use. Sulfhydryl variable (SHV) is a well-known bacterial enzyme linked to AR. SHV has a high degree of genetic diversity, resulting in the existence of numerous distinct variants. 

Methods: The PyRx AutoDock VINA was used to conduct in-silico screening of a natural compound library to assess their interaction with the SHV-1 protein. SwissADME web tools were used to predict the physicochemical, drug-likeness, and ADMET properties of the selected compounds.

Result: The compounds PSCdb00708, PSCdb00149, PSCdb00698, and PSCdb00175 bind strongly to the SHV-1 protein and interact strongly with the SHV-1 active site residues, as well as having several amino acid residue interactions in common with avibactam. These compounds exhibited higher binding affinity values than avibactam. Furthermore, these compounds demonstrated no violation of drug-likeness.

Conclusion: The compounds PSCdb00708, PSCdb00149, PSCdb00698, and PSCdb00175 can be employed as SHV-1 inhibitors in the management of AR. However, experimental validation is required to optimize them as SHV-1 inhibitors.

Keywords: Antibiotic-resistant; Antibiotic; Virtual screening; AutoDock; SHV-1 protein 


Full Text:

PDF

References


Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. The Journal of Infection in Developing Countries, (2014); 8(2): 129-136.

Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence, (2013); 4(2): 185-191.

Wright GD. Something old, something new: revisiting natural products in antibiotic drug discovery. Canadian Journal of Microbiology, (2014); 60(3): 147-154.

Sengupta S, Chattopadhyay MK, Grossart HP. The multifaceted roles of antibiotics and antibiotic resistance in nature. Frontiers in Microbiology, (2013); 4: 47.

Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clinical Infectious Diseases, (2014); 59 S(Suppl_2): S71-S75.

Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut Microbes, (2014); 5(1): 3-4.

Read AF, Woods RJ. Antibiotic resistance management. Evolution, Medicine, and Public Health, (2014); 2014(1): 147.

Lushniak BD. Antibiotic resistance: a public health crisis. Public Health Reports, (2014); 129(4): 314-316.

Gross M. Antibiotics in crisis. Current Biology, (2013); 23(24): 1063-1065.

Piddock LJ. The crisis of no new antibiotics–what is the way forward? The Lancet Infectious Diseases, (2012); 12(3): 249-253.

Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Frontiers in Public Health, (2014); 2: 145.

Livermore DM. Beta-Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews, (1995); 8(4): 557-584.

Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews, (2001); 14(4): 933-951.

Kim YK, Pai H, Lee HJ, Park SE, Choi EH, et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrobial

Agents and Chemotherapy, (2002); 46(5): 1481-1491.

Kuzin AP, Nukaga M, Nukaga Y, Hujer AM, Bonomo RA, et al. Structure of the SHV-1 β-lactamase. Biochemistry, (1999); 38(18): 5720-5727.

Pitton JS. Mechanisms of bacterial resistance to antibiotics. Ergebnisse der Physiologie Reviews of Physiology, (2010); 65: 15-93.

Matthew M, Hedges RW, Smith JT. Types of beta-lactamase determined by plasmids in gram-negative bacteria. Journal of Bacteriology, (1979); 138(3): 657-662.

Barthelemy M, Peduzzi J, Labia R. Complete amino acid sequence of p453-plasmid-mediated PIT-2 β-lactamase (SHV-1). Biochemical Journal, (1988); 251(1): 73-79.

Yu W, MacKerell AD. Computer-Aided Drug Design Methods. Methods in Molecular Biology, (2017); 1520: 85-106.

Valdes-Jimenez A, Pena-Varas C, Borrego-Munoz P, Arrue L, Alegria-Arcos M, et al. PSC-db: a structured and searchable 3D-database for plant secondary compounds. Molecules, (2021); 26(4): 1124.

Ma Y, Guo Z, Xia B, Zhang Y, Liu X, et al. Identification of antimicrobial peptides from the human gut microbiome using deep learning. Nature Biotechnology, (2022); 40(6): 921-931.

David L, Brata AM, Mogosan C, Pop C, Czako Z, et al. Artificial Intelligence and Antibiotic Discovery. Antibiotics , (2021); 10(11): 1376.

Du F, Ma J, Gong H, Bista R, Zha P, et al. Microbial Infection and Antibiotic Susceptibility of Diabetic Foot Ulcer in China: Literature Review. Frontiers in Endocrinology , (2022); 13: 881659.

Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. Journal of Natural Products, (2020); 83(3): 770-803.




DOI: http://dx.doi.org/10.62940/als.v11i4.2919

Refbacks

  • There are currently no refbacks.